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S U M M A R Y
Background: Staphylococcus aureus has emerged as a major drug-resistant pathogen in hospital- and
community-acquired infections. Leucine aminopeptidase (LAP) is known to be essential for survival of
the bacteria; however the LAP of S. aureus has not been extensively characterized. In this study, we report
a detailed characterization of the S. aureus LAP.
Methods: LAP from S. aureus was cloned, puriﬁed, and further biochemically characterized. The
expression of LAP was analyzed by Western blotting. Growth and bioﬁlm formation were analyzed
spectrophotometrically.
Results: LAP was cloned from S. aureus and expressed as a 55 kDa protein, whereas the molecular weight
of the native protein is approximately 600 kDa. LAP showed amidolytic activity against L-leucine p-
nitroanilide. Optimal activity was observed at pH 8.5 and 37 8C with a Vmax of 2500 mmol/min/mg
protein. LAP enzymatic activity was inhibited by ion chelators and enhanced by divalent metal ions,
speciﬁcally Ni. LAP is secreted by laboratory as well as clinical strains. Bestatin, an inhibitor of LAP,
inhibits S. aureus growth and bioﬁlm formation.
Conclusions: To our knowledge, this is the ﬁrst detailed characterization of LAP from S. aureus and
suggests its importance in survival and pathogenesis.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Staphylococcus aureus is one of the leading causes of hospital-
acquired infections and of mortality. It is one of the pathogens
causing more fatalities than HIV/AIDS. The emergence of
antibiotic-resistant strains and major outbreaks worldwide have
alarmed the medical community.1 The anterior nares are one of the
major ecological niches of S. aureus. Many other sites are also
colonized by S. aureus, such as the axillae, groin, and gastrointesti-
nal tract. S. aureus infections range from minor wound infections to
life-threatening conditions like endocarditis, osteomyelitis, and
septic shock.2 Therefore, it is important to understand the
molecular mechanisms of staphylococcal pathogenesis and to
identify new therapeutic targets/drug scaffolds for the develop-
ment of effective anti-Staphylococcus agents.
Aminopeptidases play a critical role in cellular metabolism and
catalyze the removal of N-terminal amino acid residues from
peptides.3 Emerging experimental evidences suggest the role for
leucine aminopeptidases (LAPs) in the survival of pathogens under* Corresponding author. Tel.: +91 79 30514240; fax: +91 79 30514110.
E-mail address: rsingh@iiar.res.in (R. Singh).
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doi:10.1016/j.ijid.2012.01.009different conditions. The LAP from Plasmodium vivax catalyzes the
removal of amino acids from the peptide generated in hemoglobin
degradation and is utilized for the growth and development of the
pathogen.4 Plasmodium falciparum parasites over-expressing LAP
are two-fold less susceptible to killing by bestatin (half-maximal
effective concentration (EC50) = 64 mM) compared to wild-type
parasites (EC50 = 25 mM).
5 LAP is upregulated in metronidazole-
resistant Helicobacter pylori.6 These experimental observations
strongly suggest a role for LAPs in the survival of pathogens in
different extreme environments and in the acquirement of drug
resistance.
LAPs and their role in the survival of Gram-negative bacteria has
been reported,7 however they are less well characterized in Gram-
positive pathogens including S. aureus. In this study, we cloned and
characterized the LAP from S. aureus.
2. Materials and methods
2.1. Bacteria and culture conditions
The standard laboratory strain of S. aureus NCTC 8325 was used
in this study and was cryopreserved at 80 8C. Clinical strains of
S. aureus (P189, P469, P768, P359, and P790) were obtained fromses. Published by Elsevier Ltd. All rights reserved.
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ology, Maulana Azad Medical College, New Delhi, India. All S.
aureus strains were cultured in nutrient broth (Himedia, India) and
incubated overnight on a shaker at 200 rpm and 37 8C. Escherichia
coli BL21-Gold (DE3) (Stratagene) and E. coli DH5a (Invitrogen)
were grown in Luria broth (LB) at 37 8C and supplemented with
appropriate antibiotics when needed. Thioredoxin A (TrxA)
antibody was provided by Dr Jan Maarten van Dij, Department
of Medical Microbiology, University Medical Center Groningen and
University of Groningen, Groningen, the Netherlands.
2.2. Cloning and expression of S. aureus LAP
Using the published sequence of the S. aureus genome (GenBank
accession number NC_007795), forward (50-CGCGGATCCAT-
GAATTTTAAATTAAAT-30) and reverse (50-CCGCTCGAGTTGTTGTTT-
TAACCATTG-30) primers were synthesized. The PCR ampliﬁed
product was cloned in pET-28a, conﬁrmed by sequencing.
LAP cloned in pET-28a was transformed in E. coli BL21-Gold
(DE3). Inoculum (1%) from culture grown overnight was inoculated
into LB, incubated at 37 8C on an orbital shaker at 200 rpm, and
induced by isopropyl-b-D-thiogalactopyranoside (IPTG). Bacteria
were harvested by centrifugation (7000 rpm, 10 min, 4 8C), resus-
pended in binding buffer A (20 mM HEPES (hydroxyethyl piper-
azineethanesulfonic acid) pH 7.4, 1.5 mM MgCl2, 100 mM NaCl, 1%
Triton, 1 mM DTT (dithiothreitol), and 1 mM PMSF (phenylmethyl-
sulfonyl ﬂuoride)) and lysed by sonication (Sonics & Materials, Inc.).
The lysate was centrifuged (15 000 rpm, 10 min, 4 8C) and the
supernatant collected. The lysate was incubated with TALON Metal
Afﬁnity Resin (Clontech Takara Bio) for 1 h at 4 8C on a Rotospin
device and washed three times with buffer A to remove non-speciﬁc
binding. The purity of LAP was evaluated on Coomassie blue-stained
12% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE). Bead-bound LAP was eluted with 100 mM ethylene-
diaminetetraacetic acid (EDTA) at 4 8C, concentrated, and the EDTA
exchanged with phosphate buffered saline (PBS) using a Centricon
(Millipore) device with 10-kDa cut-off. The protein concentration
was determined by Bradford reagent (Bio-Rad).
2.3. Blue native-PAGE (BN-PAGE)
To determine the native molecular weight of LAP, BN-PAGE was
performed as described previously,8,9 with minor modiﬁcations.
Acrylamide (50% w/v)/bis (0.5% w/v) solution was prepared that
yielded highly porous gels on polymerization, for the separation of
higher order protein complexes. The ﬁnal concentration of the
stacking gel was 4% and that of the resolving gel was 8%. Puriﬁed
LAP was mixed with sample buffer, and non-gradient BN-PAGE
was performed at room temperature as described previously.8 The
gel was stained with Coomassie brilliant blue G-250 (CBB G-250),
followed by destaining in a solution containing 10% (v/v) methanol
and 8% (v/v) acetic acid. All gel images were documented using an
Epson Perfection 1670 scanner.
2.4. In-gel activity staining
Activity staining of LAP was performed as described previous-
ly,10 with minor modiﬁcations. Brieﬂy, puriﬁed LAP was resolved
on 8% native-PAGE, as described above, and the gel washed twice
with distilled water for 10 min. The gel was equilibrated twice with
buffer B (Tris–HCl 50 mM, pH 8.5) and incubated in the presence of
substrate (0.0015% w/v leucine p-nitroanilide (LpNA) solution in
buffer A) at 30 8C for 10 min. Diazotization of liberated p-
nitroaniline was performed at room temperature by immersing
the gel into freshly made 0.1% NaNO2, 1 M HCl for 2 min. The excess
NaNO2 was removed by shaking the gel in 1% (w/v) urea. Thediazotized gel was then immersed in 0.025% (w/v) 1-naphthyl-
amine solution in 22% v/v ethanol with gentle agitation until a
distinct pink azo dye developed.
2.5. Enzymatic analysis of recombinant LAP
Kinetic analysis of LAP was performed as described earlier,11
with minor modiﬁcations. The standard reaction mixture con-
tained 50 mM Tris–HCl (pH 8.5), 1 mM MnCl2, 1 mg LAP protein,
and 1 mM of L-leucine p-nitroanilide (Sigma-Aldrich); this was
incubated at 37 8C for 15 min. The progress of the reaction was
observed by monitoring the optical density (OD) at 405 nm by
spectrophotometry.
The substrate saturation curve of LAP was determined by
incubating LAP (1 mg/ml in 50 mM Tris–HCl, and 1 mM MnCl2)
with increasing substrate concentrations from 0.1 mM to 4.5 mM.
The Michaelis–Menten constants (Km) and maximum velocity
(Vmax) were calculated from the Lineweaver–Burk plot.
To determine the optimum temperature for activity, LAP (1 mg/
ml in 50 mM Tris–HCl, and 1 mM MnCl2) was incubated at
different temperatures (15–85 8C) for 15 min before the addition of
substrate (1 mM L-leucine p-nitroanilide).
The LAP pH proﬁle was determined by incubating LAP (1 mg/ml,
37 8C, 15 min) in constant ionic strength acetate/2-(N-morpholi-
no)ethanesulfonic acid (MES)/Tris buffer (AMT buffer: 50 mM
acetic acid, 50 mM MES, and 100 mM Tris–HCl,12 pH 4–11), and
1 mM MnCl2 before addition of the substrate (1 mM L-leucine p-
nitroanilide).
The metal ion dependence of LAP was investigated by assaying
the activity after pre-incubation of the enzyme (1 mg/ml, 37 8C,
15 min) in 50 mM Tris–HCl pH 8.5, containing a speciﬁed metal
chloride (1 mM). The substrate (1 mM L-leucine p-nitroanilide)
was added and the reaction monitored spectrophotometrically as
described above.
2.6. Generation of polyclonal antibody
Polyclonal antibody was generated in a 6-month-old healthy
New Zealand white rabbit. Fifty micrograms of puriﬁed LAP with
complete Freund’s adjuvant (Sigma) was injected subcutaneously
under the arm. The rabbit was bled and serum was collected.
2.7. Western blotting
Culture of S. aureus grown overnight was centrifuged at 4 8C;
the bacterial pellet and supernatant (culture media) were
collected. The supernatant was passed through a 0.22-mM ﬁlter
to remove any bacterial cell. The pellet was lysed in PBS containing
protease inhibitor (Roche), centrifuged at 14 000 rpm at 4 8C for
15 min, and the lysate collected. The protein concentration was
determined using Bradford reagent (Bio-Rad). Equal amounts of
proteins from the different samples were resolved on 12% SDS-
PAGE and electroblotted onto a polyvinylidene ﬂuoride (PVDF)
membrane (Bio-Rad). The membrane was probed with LAP
antibody (1:7000 dilution). Similarly equal amounts of superna-
tant and lysate were loaded onto a 12% SDS-PAGE and electro-
blotted onto a PVDF membrane and probed with TrxA antibody
(1:5000 dilution). Clinical strains of S. aureus were also grown and
Western blotting performed as described above.
2.8. Effect of bestatin on LAP activity and growth of S. aureus in vitro
Bestatin is known to inhibit LAP enzymatic activity.13 The
inhibitory effect of bestatin on LAP was assayed by pre-incubation
of puriﬁed enzyme (1 mg/ml, 37 8C, 15 min) with different
concentrations of inhibitor in 50 mM Tris–HCl pH 8.5.
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grown overnight was re-inoculated in nutrient broth supplemen-
ted with increasing concentrations of bestatin and the OD600
monitored 3 h after addition of the inhibitor.
2.9. Analysis of S. aureus bioﬁlm formation in the presence of bestatin
S. aureus cultures grown overnight were diluted (1:40) in
tryptone soya broth (TSB) containing 0.25% glucose and inoculated
in sterile culture plates. Bestatin was added to a ﬁnal concentration
of 100 mg/ml. Plates were incubated at 37 8C without shaking for
16 h. Plates were washed three times with sterile water, stained
with 0.1% crystal violet for 1 min, rewashed with sterile water, and
photographed. Crystal violet was solubilized using 30% glacial




3.1. Phylogenetic analysis of LAP from S. aureus
This study focused on the characterization of the LAP of S.
aureus, an enzyme that is essential for the survival andFigure 1. Domain and phylogenetic analysis of Staphylococcus aureus LAP. (A) Analysis o
aureus NCTC 8325 was analyzed. The MEROPS database showed that it belongs to the M
domains of the M17 LAPs: protein sequences with the following accession numbers were
sapiens AAD17527, Bos taurus S65367, Solanum lycopersicum AAC49456, Rickettsia prowaz
prepared by comparing the full-length amino acid sequences of seven members of the fam
and catalytic activity (A) are boxed. (C) Phylogenetic relationship of the M17 LAP family m
acid sequences of LAP family members using the CLUSTAL W alignment tool.pathogenesis of other bacteria. Analysis of the S. aureus NCTC
8325 genome identiﬁed only one copy of a putative LAP gene,
which has thus far not been characterized. This open reading frame
(ORF) is 1496 base pairs and encodes a protein of 491 amino acids.
The protein sequence analysis of LAP showed characteristic
similarity with members of the M17 family of proteases
(Figure 1A). The alignment of the protein sequence of LAP from
S. aureus with members of the M17 family of proteases revealed
typical signature sequences and the existence of multiple
conserved amino acids within predicted functional domains. The
residues for metal binding (M) and catalytic activity (A) are
conserved across different bacteria and higher eukaryotes
(Figure 1B). The BlastP program revealed that the LAP from S.
aureus shares 35%, 34%, and 35% sequence similarity to human,
Haemophilus inﬂuenzae, and E. coli LAPs, respectively. The LAP from
S. aureus is phylogenetically closest to that of Rickettsia prowazekii,
divergent from other bacteria and human (Figure 1C).
3.2. Characterization of LAP from S. aureus
LAP was expressed as a 55 kDa protein when analyzed on 12%
SDS-PAGE (Figure 2A). The molecular weight of the native LAP was
determined by modiﬁed BN-PAGE (Figure 2B). BN-PAGE is a higherf probable LAP ORF: the probable LAP sequence (YP_499432) from Staphylococcus
17 superfamily of aminopeptidases. (B) Amino acid sequence alignment of catalytic
 analyzed: Escherichia coli NP_290893, Haemophilus inﬂuenzae ZP_00154606, Homo
ekii AJ235270, and Staphylococcus aureus YP_499432. An uprooted dendrogram was
ily using the CLUSTAL W alignment tool. The residues essential to metal binding (M)
embers: an unrooted dendrogram was prepared by comparing the full-length amino
Figure 2. Analysis of Staphylococcus aureus LAP. (A) Over-expression of LAP: LAP cloned in pET-28a was induced by addition of IPTG (1 mM) at room temperature for 4 h. The
bacterial pellet was lysed and the protein puriﬁed, resolved on 12% SDS-PAGE, and stained with Coomassie brilliant blue. (B) Native molecular weight determination: the
native molecular weight of LAP was determined by resolving the puriﬁed LAP on 8% BN-PAGE at room temperature with rat liver mitochondrial respiratory chain complexes
as reference molecular weight. (C) In-gel activity of LAP: the puriﬁed LAP was loaded onto 8% native PAGE and the gel was washed twice with distilled water and then with
50 mM Tris–HCl pH 8.5. The gel was incubated with 0.0015% substrate and diazotization was done as described in the Materials and methods section.
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molecular weight proteins (kDa) and multi-protein complexes
(MDa). It has recently been observed that BN-PAGE has higher
resolution than gel ﬁltration or sucrose density ultracentrifugation,
and BN-PAGE has been used to resolve many higher order protein
complexes in bacteria.15,16 Using BN-PAGE, the molecular weight
of LAP was found to be approximately 600 kDa, which indicates
that the LAP may be a dodecamer in native form. Puriﬁed LAP was
separated on native-PAGE, and incubation with the substrate
resulted in the development of a pink azo dye (Figure 2C),
suggesting that our puriﬁed LAP was enzymatically active.
3.3. Biochemical characterization of LAP
We carried out biochemical characterization of the puriﬁed LAP
and determined several enzyme kinetics parameters. The Km and
Vmax for LAP were determined using leucine p-nitroanilide as
substrate at concentrations ranging from 0.1 mM to 4.5 mM. Their
values were calculated respectively from the x and y intercepts of
the double-reciprocal plot of substrate concentration (mM) versus
LAP activity. Km and Vmax values were found to be 10 mM and
2500 mmol/min/mg protein, respectively (Figure 3, A and B).
Amidolytic activity against L-leucine p-nitroanilide was optimal
at pH 8.5 and detectable at up to pH 10.5 (Figure 3C). The activities
declined sharply at further alkaline pH and even under moderate
acidic conditions (pH 5.0). LAP activity was determined at different
temperatures in the range of 5–100 8C, and optimal activity was
observed at 37 8C. The activity declined sharply at higher and lower
temperatures (Figure 3D).
LAP belongs to the M17 family, which consists of metalloami-
nopeptidases with a broad range of preferences for metal ions. LAP
showed enhanced activity in the presence of metal ions including
Mn2+, Co2+, and Ni2+. The maximum activity was observed in the
presence of Ni2+, followed by Mn2+ and Co2+. The activity was
inhibited by metal ion chelators such as EDTA. PMSF did not show
any effect on enzymatic activity, which shows that it did not
exhibit serine protease activity (Figure 3E).3.4. LAP of S. aureus is secreted
The virulence factors of many pathogenic bacteria are secreted
into the extracellular milieu and play a critical role in infection.17,18
We investigated if LAP is secreted by S. aureus. The polyclonal
antibody raised was speciﬁc to LAP, as it recognized a protein of
55 kDa corresponding to the LAP of S. aureus and showed no cross-
reactivity with other proteins in the lysate.
The Western blotting of the supernatant and lysate of S. aureus
culture grown overnight showed immunoreactivity against the
protein of 55 kDa in the lysate as well as in the supernatant
(culture media). The presence of signiﬁcant amounts of LAP in the
supernatant was surprising and suggests the possibility of
bacterial lysis. To eliminate this possibility, Western blotting of
a known intracellular protein – thioredoxin A (TrxA) – was
performed under similar conditions. TrxA is a cytoplasmic
bacterial protein that facilitates the reduction of cysteine
disulﬁdes of other cytoplasmic proteins and acts as an antioxi-
dant. Since TrxA is normally a cytoplasmic protein, it would only
be found in the extracellular milieu if the bacterial cells
underwent lysis under similar culture conditions.19 The Western
blot analysis showed a protein of 10 kDa corresponding to TrxA
only in the cell lysate, and no corresponding band was detected in
the supernatant (culture media). This strongly suggests that LAP is
secreted by a regulated process rather than by cell lysis
(Figure 4A).
LAP expression was also examined in lysates and supernatants
of ﬁve methicillin-sensitive clinical strains of S. aureus (MSSA)
grown under similar conditions and processed in the same way.
We clearly observed immunoreactivity against a 55 kDa protein,
corresponding to LAP, in the lysates as well as in the supernatants
(culture media) of the clinical strains P469, P768, P359, and P790
(Figure 4B). Interestingly a low level of LAP was observed in the
lysate as well as the supernatant of one of the clinical strains, P189
(Figure 4B). It will be interesting to further compare the
pathogenesis of P189 as compared to other clinical strains
(P469, P768, P359, and P790).
Figure 3. Biochemical characterization of LAP. (A) Substrate saturation curve of LAP: the experiment was performed with 50 mM Tris–HCl pH 8.5 and 1 mM MnCl2, with
substrate concentrations from 0.1 mM to 4.5 mM. (B) Km and Vmax of LAP: Km and Vmax of LAP were calculated from the intercepts of the Lineweaver–Burk plot. (C) Effects of
pH on LAP activity: the experiments were performed over the pH range 4–11 in 50 mM Tris–HCl pH 8.5 with 1 mM MnCl2 and 1 mM substrate. Data shown are standard error
of the mean (SEM) (n = 3). (D) Effects of temperature on LAP activity: the experiments were carried out in Tris–HCl buffer pH 8.5 over a temperature range of 5–100 8C with
1 mM MnCl2 and 1 mM substrate. Data shown are SEM (n = 3). (E) Effect of metal ions on LAP activity: the effect of metal ions on the LAP activity was assayed in the presence of
different metal ions (1 mM concentration) in 50 mM Tris–HCl pH 8.5. Data shown are SEM (n = 3).
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formation
Bestatin is a potent and speciﬁc inhibitor of LAP, as described
previously.20 The enzymatic activity of puriﬁed LAP was assayed
in the presence of bestatin. LAP activity decreased with
increasing concentration of bestatin. The calculated half-maxi-
mal inhibitory concentration (IC50) was found to be 410 nM
(Figure 5A).
An earlier report strongly suggested that the LAP family of
proteases may be important for survival of the pathogen during
infection.21 In the current study, the growth of S. aureus was
inhibited in the presence of bestatin and decreased in a dose-
dependent manner (Figure 5B). This strongly suggests that the
activity of LAP may be essential for S. aureus survival.Bioﬁlm formation is an important microbial survival strategy,
since bacteria encased in bioﬁlm have increased resistance to
antibiotics as well as immune clearance.22 We therefore examined
whether bestatin had an effect on bioﬁlm formation in S. aureus.
The presence of bestatin signiﬁcantly inhibited bioﬁlm formation
(Figure 5, C and D).
4. Discussion
Virulence factors produced by S. aureus include large families of
secreted exotoxins that facilitate disease progression and many
secreted proteases that may help them to catabolize exogenous
proteins and promote the survival of bacteria under extreme
conditions.23 LAPs are known to be important for bacterial
physiology and have not yet been characterized in many
Figure 4. Extracellular secretion of LAP. (A) Detection of LAP in the supernatant of
Staphylococcus aureus: puriﬁed LAP, supernatant (culture media), and lysate of S.
aureus was resolved on 12% SDS-PAGE, transferred to a PVDF membrane, and
blotted with LAP antibody. For control, the same amount of lysate and supernatant
of S. aureus, from the same sample was resolved on 12% SDS-PAGE and blotted with
TrxA antibody. (B) Extracellular secretion of LAP from pathogenic strains:
supernatants (culture media) and lysates of clinical S. aureus were resolved on
12% SDS-PAGE, transferred to a PVDF membrane, and blotted with LAP antibody.
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have characterized LAP from S. aureus for the ﬁrst time; this LAP is
secreted into the extracellular milieu and is important for bacterial
growth and bioﬁlm formation.Figure 5. Bestatin inhibits LAP activity, growth of Staphylococcus aureus, and bioﬁlm fo
carried out by pre-incubation of LAP (1 mg/ml) with different concentrations of bestatin in
Data shown are standard error of the mean (SEM) (n = 3). (B) Bestatin inhibits the growth 
of bestatin at 37 8C, and growth was monitored by measuring OD600 3 h after addition of 
of S. aureus: culture of S. aureus grown overnight was diluted in TSB (1:40 dilution) conta
of inoculation at a concentration of 100 mg/ml and incubated at 37 8C for 16 h. Bioﬁlm w
formation: bioﬁlm was stained with 0.1% crystal violet for 1 min and washed three times
OD measured at 562 nM. Data shown are SEM (n = 3).The ORF encoding the S. aureus LAP contains the characteristic
catalytic signature sequence of the M17 family of proteases from
other organisms.24 This protein exhibited catalytic and metal
binding properties, which are conserved across different species.
Phylogenetic analysis clearly demonstrated that the S. aureus LAP
is most closely related to that of R. prowazekii. Interestingly many
pathogenic mechanisms of Rickettsia are similar to those of S.
aureus.25 However, the role of LAP in host–pathogen interactions
in Rickettsia and other bacterial pathogens has yet to be
demonstrated.
The LAPs from bacteria and other species have been demon-
strated to form hexameric complexes;26 however evidence from
the current study suggests that the LAP from S. aureus may exist as
a dodecamer or forms higher molecular order structures. This
needs to be further validated by other chromatographic techni-
ques. Analysis of the S. aureus genome suggests that LAP is present
as a single copy, and thus may exhibit a broad substrate spectrum
to ensure adequate release of amino acids from polypeptides to
maintain the life cycle in different stressed conditions. Therefore,
the aminopeptidase activity against other substrates (Met, Arg, Ala,
Ile, Val, Phe, Gly, and Tyr) should be studied further.
LAPs belong to the M17 family of metalloproteases, which
mainly prefer Zn(II),27 and other aminopeptidases are dependent
upon Mn(II),28 Fe(II),29 and Zn(II).30 In the present study we
observed that the S. aureus LAP exhibited maximum activity in the
presence of Ni(II), indicating that it has a preference for metals
distinct from those of other M17 proteases.
Bestatin is a dipeptide analogue that has been identiﬁed as an
inhibitor of LAP.31 Bestatin inhibited LAP enzymatic activity as well
as S. aureus growth, suggesting that LAP activity may be importantrmation. (A) Bestatin inhibits the enzymatic activity of LAP: the experiments were
 Tris–HCl buffer (pH 8.5) and further with 1 mM MnCl2 and 1 mM substrate at 37 8C.
of S. aureus in vitro: S. aureus was incubated with or without different concentrations
the inhibitor. Data shown are SEM (n = 3). (C) Bestatin inhibits the bioﬁlm formation
ining 0.25% glucose and inoculated in 24-well plates. Bestatin was added at the time
as stained with 0.1% crystal violet and photographed. (D) Quantiﬁcation of bioﬁlm
 with sterile water. Crystal violet was solubilized with 30% glacial acetic acid and the
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pathogens like Fasicola, LAP has been observed to be secreted and
found to be important for evasion from the host immune
response.21 Similarly secreted LAP from Legionella pneumophila
may be important for infectivity in multiple hosts, including
humans.32 In consonance with earlier observations,21 we found
that LAP was predominantly secreted in the extracellular milieu
from S. aureus NCTC 8325, as well as in clinical strains of S. aureus
(MSSA). This strongly suggests that LAP may be important not only
for bacterial physiology but also for pathogenesis. This is an
important ﬁnding and needs further study to establish the role of
LAP in the pathogenesis of S. aureus.
The development of persistent infection is mainly attributed to
bioﬁlm formation, which is implicated in many diseases like cystic
ﬁbrosis, chronic rhinosinusitis, and pneumonia.33 Data from the
current study strongly suggest that secreted LAP may have a role in
the process of S. aureus bioﬁlm formation, which may be one of the
important mechanisms in the development of resistance to
antibiotics. It has also been demonstrated previously that bioﬁlms
are more resistant to antibiotics as compared to their planktonic
counterparts.34 The inhibition of bioﬁlm formation suggests that
bestatin could be a quorum sensing inhibitor for S. aureus, however
this requires further experimental evidence. Bestatin may be an
interesting scaffold on which to design novel inhibitors of S. aureus,
and thus may be a helpful tool in the development of an effective
strategy to combat this pathogen.
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